Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This trial intends: 1.To evaluate the concentration of Chidamide in the serum and
cerebral-spinal fluid of PTCL patients at certain time points after taking the medicine, to
evaluate the pharmacokinetics of Chidamide in these patients and its CNS (central nervous
system) distribution.
2. To evaluate the efficiency and safety of Chidamide in PTCL patients.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital